Abstract
An enrichment medium was developed and evaluated for isolation of fluconazole-resistant minority yeast species in a hospital setting. The enrichment medium was made by adding fluconazole (10 µg/ml) to yeast nitrogen base/glucose broth. Under laboratory conditions the broth permitted detection of 20 of 20Candida krusei isolates and 20 of 20Candida glabrata isolates in mixtures withCandida albicans even when theCandida albicans cells outnumbered those of the other species by 1000:1. Results of culture on the enrichment medium were compared with those obtained on routine agar media and on a yeast differential agar which facilitates detection of mixed yeast species by their colony colours. Only oneCandida glabrata isolate was detected on the enrichment broth but not found on routine culture of 68 yeast-positive clinical specimens. However, bacterial over-growth in some broths may have retarded the appearance of other yeast isolates. On the yeast differential agar, 20 clinical specimens were found to contain mixtures of yeast species compared with only 2 on routine culture.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Casasnovas RO, Caillot D, Solary E, Bonotte B, Chavanet P, Bonin A: Prophylactic fluconazole andCandida krusei infection. New England Journal of Medicine 1992, 326: 891–892.
Coste T, Barale T, Reboux G, Talon D, Cahn JY: Prophylaxie antifongique par fluconazole: son influence sur l'augmentation de la fréquence d'isolement deCandida glabrata. Bulletin de la Société Française de Mycologie Médicale 1990, 19: 151–154.
Dupont B, Graybill JR, Armstrong D, Laroch R, Touze JE, Wheat LJ: Fungal infections in AIDS patients. Journal of Medical and Veterinary Mycology 1992, 26: 67–71.
Ellis ME, Hussain Qadri SM, Spence D, Halim MA, Ernst P, Clink H, Baillie F, De Vol EB: The effect of fluconazole as prophylaxis for neutropenic patients on the isolation ofCandida spp. from surveillance cultures. Journal of Antimicrobial Chemotherapy 1994, 33: 1223–1228.
Fan-Harvard P, Capano D, Smith SM, Mangia A, Eng RHK: Development of resistance in candida isolates from patients recelving prolonged antifungal therapy. Antimicrobial Agents and Chemotherapy 1991, 35: 2302–2305.
Just-Nubling G, Gentschew G, Döhle M, Böttinger C, Helm EB, Stille W: Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients. Mycoses 1990, 33: 435–440.
Millon L, Reboux G, Barale T: Émergence deCandida glabrata etCandida krusei chez des patients séropositifs pour le VIH atteints de candidose oropharyngée, traités de façon prolongée par le fluconazole. Journal de Mycologie Médicale 1994, 4: 90–92.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274–1277.
Odds FC: Candida and candidosis. Second edition. Bailliere-Tindall, London, 1988, p. 68–92.
Odds FC, Bernaerts R: CHROMagar® Candida, a new, differential isolation medium for the presumptive identification of clinically importantCandida species. Journal of Clinical Microbiology 1994, 32: 1923–1929.
Troke PF: In vitro and experimental in vivo activities of fluconazole against some fungi causing cutaneous mycoses. In: Rippon JW, Fromtling RA (ed.): Cutaneous antifungal agents. Marcel Dekker, New York, 1993, p. 199–274.
Odds FC: Effects of temperature on anti-Candida activity of antifungal antibiotics. Antimicrobial Agents and Chemotherapy 1993, 37: 685–691.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Louwagie, B., Surmont, I., Verhaegen, J. et al. Differential and enrichment media for selective culture and recognition of yeast species from clinical material. Eur. J. Clin. Microbiol. Infect. Dis. 14, 406–411 (1995). https://doi.org/10.1007/BF02114896
Issue Date:
DOI: https://doi.org/10.1007/BF02114896